Genmab - Begivenhedskalender for pipelinen
'
Q3/Q4 2018
Fase
III-data (MAIA) med Darzalex + Rd i nydiagnosticeret knoglemarvskræft
16. oktober 2018
Johnson & Johnson (Janssen) Q3 2018 - Darzalex salg
24. oktober 2018
Symphony Health Solutions - Darzalex-salgstal for september
Q3/Q4 2018
Fase
III-data (Cassiopeia) med Darzalex + Vtd i nydiagnosticeret knoglemarvskræft
Q3/Q4 2018
Annoncere studie i andre cancer-former for tisotumab vedotin
Q3/Q4 2018
Yderligere data for tisotumab vedotin
14. november
Genmab Q3 2018
21. november
Symphony Health Solutions - Darzalex-salgstal for oktober
ASH kræftkonference i San Diego
Symphony Health Solutions - Darzalex-salgstal for november
2019
Fase III-data for Arzerra (ofatumumab) i attakvis multipel sklerose (RRMS)
https://markets.sydbank.dk/PublicationsWebHandler/Default.aspx?ID=0042061-056801
'
Q3/Q4 2018
Fase
III-data (MAIA) med Darzalex + Rd i nydiagnosticeret knoglemarvskræft
16. oktober 2018
Johnson & Johnson (Janssen) Q3 2018 - Darzalex salg
24. oktober 2018
Symphony Health Solutions - Darzalex-salgstal for september
Q3/Q4 2018
Fase
III-data (Cassiopeia) med Darzalex + Vtd i nydiagnosticeret knoglemarvskræft
Q3/Q4 2018
Annoncere studie i andre cancer-former for tisotumab vedotin
Q3/Q4 2018
Yderligere data for tisotumab vedotin
14. november
Genmab Q3 2018
21. november
Symphony Health Solutions - Darzalex-salgstal for oktober
ASH kræftkonference i San Diego
Symphony Health Solutions - Darzalex-salgstal for november
2019
Fase III-data for Arzerra (ofatumumab) i attakvis multipel sklerose (RRMS)
https://markets.sydbank.dk/PublicationsWebHandler/Default.aspx?ID=0042061-056801
